• Riociguat fails to improve idiopathic interstitial pneumonia-associated pulmonary hypertension: RISE-IIP

    One year ago - By Healio

    Among patients with idiopathic interstitial pneumonia associated with pulmonary hypertension, treatment with riociguat was linked to an increase in adverse events with no significant evidence of benefit, according to the RISE-IIP trial.
    In fact, the international, multicenter, double-blind, randomized, placebo-controlled phase 2b trial was terminated early due to a higher incidence of deaths, serious adverse events and adverse event-related drug discontinuations in patients treated with riociguat vs. placebo, researchers wrote in The Lancet Respiratory Medicine.
    During the main
    Read more ...